Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Willingness and ability to sign and date the study-specific informed consent form.
• Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study.
• Age greater than 18yo.
• Stage I-III TNBC or stage IV TNBC with intact breast primary.
• Planned combined ICI therapy as per SoC by treating oncologist.
Locations
United States
Pennsylvania
Penn State Health College of Medicine
RECRUITING
Hershey
Contact Information
Primary
Rebecca Jordan, M.A.
rjordan@pennstatehealth.psu.edu
717-531-0003
Time Frame
Start Date: 2023-09-01
Estimated Completion Date: 2031-09-01
Participants
Target number of participants: 20
Treatments
Experimental: Contrast Enhanced Ultrasound (with Lumason)
Related Therapeutic Areas
Sponsors
Leads: Milton S. Hershey Medical Center